Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2009

Merck & Co. Acquires Rights to C. Difficile Drugs from Medarex and MBL for $60M

Merck & Co. Acquires Rights to <i>C. Difficile</i> Drugs from Medarex and MBL for $60M

Merck & Co. to pay $60 upfront for C.Difficile treatment

  • Medarex and Massachusetts Biologic Laboratories (MBL) have out-licensed to Merck & Co. an antibody combination that targets C. difficile in a deal worth over $225 million. Merck gains the worldwide rights to market and further develop the CDA-1 and CDB-1 antibody combination and will pay Medarex and MBL $60 million up front.

    A further $165 million will be paid upon the completion of certain milestones. Medarex and MBL will recieve double-digit royalties and milestones if certain sales levels are met. Pursuant to a prior co-development agreement, Medarex and MBL will divide all payments equally.

    A Phase II multicenter, randomized, double-blind trial showed a reduction in the incidence of infection among 200 patients when compared to those taking a placebo, says Merck. An oral presentation of the results is slated for June 2 at Digestive Disease Week.ADNFCR-2184-ID-19131120-ADNFCR



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »